Your Messages Inbox
Your Article Summary
See Latest ArticlesMerck Statement About JANUVIA™ (sitagliptin) and JANUMET™
Merck & Co., 09/28/09
JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate. JANUMET and JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUMET and JANUVIA have not been studied in combination with insulin.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Freeze-Thaw Performance and Robustness Assessment of Celsius FFT 6L
BioPharm, 12/09/09
Bivariate Random Effects Meta-Analysis of Diagnostic Studies Using Generalized Linear Mixed Models
Medical Decision Making, 12/09/09
The Impact of Disposables on Project Economics in a New Antibody Plant
BioPharm, 12/09/09
Article Search
Sponsor